1
|
Mohamadizadeh M, Dehghan P, Azizi-Soleiman F, Maleki P. Effectiveness of date seed on glycemia and advanced glycation end-products in type 2 diabetes: a randomized placebo-controlled trial. Nutr Diabetes 2024; 14:37. [PMID: 38824123 PMCID: PMC11144252 DOI: 10.1038/s41387-024-00287-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Revised: 04/28/2024] [Accepted: 04/30/2024] [Indexed: 06/03/2024] Open
Abstract
BACKGROUND Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting more than 95% of people with diabetes. Traditionally, some medicinal plants have been considered as an effective approach in management of T2DM. This trial evaluated the effects of date seed powder (DSP) on glycemia indices and oxidative stress in T2DM patients. METHODS In this trail, 43 patients with T2DM were randomized to two groups: either 5 g/d of the DSP or placebo for 8 weeks. Levels of glycemic indices, lipolpolysaccharide (LPS), and soluble receptor for advanced glycation end products (s-RAGE), as well as other parameters associated with oxidative stress were assessed at baseline and after 8 weeks. Independent t-test and analysis of covariance (ANCOVA) were used for between-groups comparisons at baseline and the post-intervention phase, respectively. RESULTS The results showed that supplementation with DSP significantly decreased HbA1c (-0.30 ± 0.48%), insulin (-1.70 ± 2.21 μU/ml), HOMA-IR (-1.05 ± 0.21), HOMA-B (-0.76 ± 21.21), lipopolysaccharide (LPS) (-3.68 ± 6.05 EU/mL), and pentosidine (118.99 ± 21.67 pg/mL) (P < 0.05, ANCOVA adjusted for baseline and confounding factors). On the other hand, DSP supplementation significantly increased total antioxidant capacity (TAC) (0.50 ± 0.26 mmol/L), superoxide dismutase (SOD) (0.69 ± 0.32 U/ml), and s-RAGE (240.13 ± 54.25 pg/mL) compared to the placebo group. FPG, hs-CRP, GPx, CML, and uric acid had no significant within- or between-group changes. CONCLUSION Supplementation of DSP could be considered an effective strategy to improve glycemic control and oxidative stress in T2DM patients (Registration ID at www.irct.ir : IRCT20150205020965N10).
Collapse
Affiliation(s)
- Mehdi Mohamadizadeh
- Student Research Committee, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Parvin Dehghan
- Department of Biochemistry and Diet Therapy, Nutrition Research Center, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
| | - Fatemeh Azizi-Soleiman
- Department of Nutrition, School of Health, Arak University of Medical Sciences, Arak, Iran.
| | - Parham Maleki
- Student Research Committee, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
2
|
Li X, Chen W, Xia J, Pan D, Sun G. The Effects of Cranberry Consumption on Glycemic and Lipid Profiles in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2024; 16:782. [PMID: 38542695 PMCID: PMC10974925 DOI: 10.3390/nu16060782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2024] [Revised: 03/06/2024] [Accepted: 03/08/2024] [Indexed: 04/09/2024] Open
Abstract
This study aims to update the evidence and clarify whether cranberry possesses lipid-lowering and hypoglycemic properties in humans. PubMed, Web of Science, and Scopus were searched to identify relevant articles published up to December 2023. In total, 3145 publications were reviewed and 16 of them were included for qualitative synthesis and meta-analysis. Stata 15.0 and Review Manager 5.4 were applied for statistical analyses. The results revealed a significant decrease in the total cholesterol to high-density lipoprotein cholesterol ratio (TC/HDL-C) (MD = -0.24; 95% CI: -0.45, -0.04; peffect = 0.02) and homeostasis model assessment of insulin resistance (HOMA-IR) (MD = -0.59; 95% CI: -1.05, -0.14; peffect = 0.01) with cranberry consumption. However, it did not influence total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), fasting blood glucose (FBG), glycated hemoglobin (HbA1c), and fasting insulin. In subgroup analysis, cranberry consumption in dried form (capsules, powder, and tablets) was found to significantly decrease the fasting insulin level (three studies, one hundred sixty-five participants, MD = -2.16; 95% CI: -4.24, -0.07; peffect = 0.04), while intervention duration, health conditions, and dosage of polyphenols and anthocyanins had no impact on blood lipid and glycemic parameters. In summary, cranberry might have potential benefits in regulating lipid and glucose profiles.
Collapse
Affiliation(s)
| | | | | | | | - Guiju Sun
- Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Southeast University, Nanjing 210009, China
| |
Collapse
|
3
|
Weh KM, Howard CL, Zhang Y, Tripp BA, Clarke JL, Howell AB, Rubenstein JH, Abrams JA, Westerhoff M, Kresty LA. Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome. JCI Insight 2024; 9:e168112. [PMID: 38329812 PMCID: PMC11063939 DOI: 10.1172/jci.insight.168112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Accepted: 02/02/2024] [Indexed: 02/10/2024] Open
Abstract
The gut and local esophageal microbiome progressively shift from healthy commensal bacteria to inflammation-linked pathogenic bacteria in patients with gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma (EAC). However, mechanisms by which microbial communities and metabolites contribute to reflux-driven EAC remain incompletely understood and challenging to target. Herein, we utilized a rat reflux-induced EAC model to investigate targeting the gut microbiome-esophageal metabolome axis with cranberry proanthocyanidins (C-PAC) to inhibit EAC progression. Sprague-Dawley rats, with or without reflux induction, received water or C-PAC ad libitum (700 μg/rat/day) for 25 or 40 weeks. C-PAC exerted prebiotic activity abrogating reflux-induced dysbiosis and mitigating bile acid metabolism and transport, culminating in significant inhibition of EAC through TLR/NF-κB/TP53 signaling cascades. At the species level, C-PAC mitigated reflux-induced pathogenic bacteria (Streptococcus parasanguinis, Escherichia coli, and Proteus mirabilis). C-PAC specifically reversed reflux-induced bacterial, inflammatory, and immune-implicated proteins and genes, including Ccl4, Cd14, Crp, Cxcl1, Il6, Il1b, Lbp, Lcn2, Myd88, Nfkb1, Tlr2, and Tlr4, aligning with changes in human EAC progression, as confirmed through public databases. C-PAC is a safe, promising dietary constituent that may be utilized alone or potentially as an adjuvant to current therapies to prevent EAC progression through ameliorating reflux-induced dysbiosis, inflammation, and cellular damage.
Collapse
Affiliation(s)
- Katherine M. Weh
- Department of Surgery, Section of Thoracic Surgery, and
- Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA
| | - Connor L. Howard
- Department of Surgery, Section of Thoracic Surgery, and
- Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA
| | - Yun Zhang
- Department of Surgery, Section of Thoracic Surgery, and
- Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA
| | | | - Jennifer L. Clarke
- Department of Statistics, Department of Food Science Technology, Quantitative Life Sciences Initiative, University of Nebraska-Lincoln, Lincoln, Nebraska, USA
| | - Amy B. Howell
- Marucci Center for Blueberry and Cranberry Research, Rutgers University, Chatsworth, New Jersey, USA
| | - Joel H. Rubenstein
- Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
- LTC Charles S. Kettles Veterans Affairs Medical Center, Ann Arbor, Michigan, USA
| | - Julian A. Abrams
- Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
| | - Maria Westerhoff
- Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
| | - Laura A. Kresty
- Department of Surgery, Section of Thoracic Surgery, and
- Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA
| |
Collapse
|
4
|
Delpino FM, Dos Santos FS, Flores TR, Cerqueira HS, Santos HO. The effects of blueberry and cranberry supplementation on blood pressure in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized clinical trials. Phytother Res 2024; 38:646-661. [PMID: 37963472 DOI: 10.1002/ptr.8069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2023] [Revised: 09/18/2023] [Accepted: 10/31/2023] [Indexed: 11/16/2023]
Abstract
Blueberries and cranberries are berry fruits with the highest number of randomized clinical trials (RCTs) focusing on blood pressure (BP). This systematic review and meta-analysis of RCTs analyzed the effects of blueberry and cranberry supplementation alone and in concert with systolic BP (SBP) and diastolic BP (DBP) in patients with cardiometabolic diseases. The searches were performed until August 2023 in the following databases: PubMed, Scopus, Web of Science, Cochrane, and Embase. Studies that examined the effects of blueberry or cranberry intake/supplementation were included. The risk of bias was evaluated using the Rob 2 scale. A meta-analysis was performed to estimate the effects of blueberry and cranberry supplementation on BP levels in patients with cardiometabolic diseases. A total of 17 articles were included, from which two found significant results from blueberry and/or cranberry supplementation in reducing BP. Pooled results revealed statistically non-significant reductions of -0.81 mm Hg for SBP (95% confidence interval [CI]: -2.26, 0.63; I2 = 0%) and -0.15 mm Hg for DBP (95% CI: -1.36, 1.05; I2 = 27%). Blueberry and/or cranberry supplementation had neutral effects on SBP and DBP in patients with cardiometabolic diseases, regardless of duration or age. Further high-quality studies are needed to firmly establish clinical efficacy.
Collapse
Affiliation(s)
| | - Francine Silva Dos Santos
- Department of Nutrition, School of Public Health, University of São Paulo, São Paulo, Brazil
- Center for Epidemiological Research in Nutrition and Health, University of São Paulo, São Paulo, Brazil
| | - Thaynã Ramos Flores
- Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, Brazil
| | | | | |
Collapse
|
5
|
Weh KM, Howard CL, Zhang Y, Tripp BA, Clarke JL, Howell AB, Rubenstein JH, Abrams JA, Westerhoff M, Kresty LA. Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.08.22.554315. [PMID: 37662411 PMCID: PMC10473615 DOI: 10.1101/2023.08.22.554315] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
The gut and local esophageal microbiome progressively shift from healthy commensal bacteria to inflammatory-linked pathogenic bacteria in patients with gastroesophageal reflux disease, Barrett's esophagus and esophageal adenocarcinoma (EAC). However, mechanisms by which microbial communities and metabolites contribute to reflux-driven EAC remain incompletely understood and challenging to target. Herein, we utilized a rat reflux-induced EAC model to investigate targeting the gut microbiome-esophageal metabolome axis with cranberry proanthocyanidins (C-PAC) to inhibit EAC progression. Sprague Dawley rats, with or without reflux-induction received water or C-PAC ad libitum (700 µg/rat/day) for 25 or 40 weeks. C-PAC exerted prebiotic activity abrogating reflux-induced dysbiosis, and mitigating bile acid metabolism and transport, culminating in significant inhibition of EAC through TLR/NF-κB/P53 signaling cascades. At the species level, C-PAC mitigated reflux-induced pathogenic bacteria (Clostridium perfringens, Escherichia coli, and Proteus mirabilis). C-PAC specifically reversed reflux-induced bacterial, inflammatory and immune-implicated proteins and genes including Ccl4, Cd14, Crp, Cxcl1, Il6, Il1β, Lbp, Lcn2, Myd88, Nfkb1, Tlr2 and Tlr4 aligning with changes in human EAC progression, as confirmed through public databases. C-PAC is a safe promising dietary constituent that may be utilized alone or potentially as an adjuvant to current therapies to prevent EAC progression through ameliorating reflux-induced dysbiosis, inflammation and cellular damage.
Collapse
|
6
|
Stote KS, Burns G, Mears K, Sweeney M, Blanton C. The Effect of Berry Consumption on Oxidative Stress Biomarkers: A Systematic Review of Randomized Controlled Trials in Humans. Antioxidants (Basel) 2023; 12:1443. [PMID: 37507981 PMCID: PMC10376627 DOI: 10.3390/antiox12071443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 07/08/2023] [Accepted: 07/10/2023] [Indexed: 07/30/2023] Open
Abstract
Bioactive compounds in berries may scavenge reactive oxygen and nitrogen species by donating electrons to free radicals, thereby protecting DNA, proteins, and lipids from oxidative damage. Evidence shows that berry consumption has beneficial health effects, though it remains unclear whether berries exert a significant impact on oxidative stress in humans. Thus, we performed a systematic review of randomized controlled trials (RCT) to examine the effects of non-acute (more than a single dose and ≥7 days) berry consumption on biomarkers of oxidative stress. Searches were conducted in PubMed, Cochrane Library, and Scopus; results were imported into Covidence for screening and data extraction. The literature search identified 622 studies that were screened, and 131 full-text studies assessed for eligibility. Ultimately, 28 RCTs met the eligibility criteria. Common biomarkers of oxidative stress (antioxidants, DNA damage, isoprostanes, malondialdehyde, and oxidized LDL) were systematically reviewed, and results were reported narratively. Of the approximate 56 oxidative stress biomarkers evaluated in the 28 RCTs, 32% of the biomarkers were reported to have statistically significant beneficial results and 68% of the biomarkers were reported as having no statistically significant differences. More well-designed and longer-term berry RCTs are needed to evaluate biomarkers of oxidative stress.
Collapse
Affiliation(s)
- Kim S Stote
- Department of Allied Health Sciences, State University of New York, Empire State University, Saratoga Springs, NY 12866, USA
| | - Gracie Burns
- Department of Biology, University of Prince Edward Island, Charlottetown, PE C1A 4P3, Canada
| | - Kim Mears
- Robertson Library, University of Prince Edward Island, Charlottetown, PE C1A 4P3, Canada
| | - Marva Sweeney
- Department of Biology, University of Prince Edward Island, Charlottetown, PE C1A 4P3, Canada
| | - Cynthia Blanton
- Department of Nutrition and Dietetics, Idaho State University, Pocatello, ID 83201, USA
| |
Collapse
|
7
|
Helm MM, Alaba T, Klimis-Zacas D, Izuora K, Basu A. Effect of Dietary Berry Supplementation on Antioxidant Biomarkers in Adults with Cardiometabolic Risks: A Systematic Review of Clinical Trials. Antioxidants (Basel) 2023; 12:1182. [PMID: 37371912 DOI: 10.3390/antiox12061182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2023] [Revised: 05/29/2023] [Accepted: 05/29/2023] [Indexed: 06/29/2023] Open
Abstract
Cardiometabolic conditions are closely associated with inflammation and oxidative stress. Dietary berries may serve as a beneficial nutrition intervention to address the features of cardiometabolic dysfunction and associated oxidative stress. The high antioxidant status of dietary berries may increase antioxidant capacity and reduce biomarkers of oxidative stress. This systematic review was conducted to investigate these effects of dietary berries. The search was conducted using PubMed, Cochrane Library, Web of Science, and citation searching. Through this search we identified 6309 articles and 54 were included in the review. Each study's risk of bias was assessed using the 2019 Cochrane Methods' Risk of Bias 2 tool. Antioxidant and oxidative stress outcomes were evaluated, and the magnitude of effect was calculated using Cohen's d. A range of effectiveness was reported in the included studies and the quality of the studies differed between the parallel and crossover trials. Considering the inconsistency in reported effectiveness, future investigations are warranted to determine the acute and sustained reductions of oxidative stress biomarkers from dietary berry intake (PROSPERO registration# CRD42022374654).
Collapse
Affiliation(s)
- Macy M Helm
- Department of Kinesiology and Nutrition Sciences, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV 89154, USA
| | - Tolu Alaba
- School of Food and Agriculture, University of Maine, Orono, ME 04469, USA
- Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME 04469, USA
| | - Dorothy Klimis-Zacas
- School of Food and Agriculture, University of Maine, Orono, ME 04469, USA
- Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME 04469, USA
| | - Kenneth Izuora
- Section of Endocrinology, Department of Internal Medicine, University of Nevada, Las Vegas, NV 89102, USA
| | - Arpita Basu
- Department of Kinesiology and Nutrition Sciences, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV 89154, USA
| |
Collapse
|
8
|
Huang H, Luo Y, Wang Q, Zhang Y, Li Z, He R, Chen X, Dong Z. Vaccinium as Potential Therapy for Diabetes and Microvascular Complications. Nutrients 2023; 15:2031. [PMID: 37432140 DOI: 10.3390/nu15092031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 04/15/2023] [Accepted: 04/20/2023] [Indexed: 07/12/2023] Open
Abstract
Diabetes mellitus is one of the most critical global health concerns, with a fast-growing prevalence. The incidence of diabetic vascular complications is also rapidly increasing, exacerbating the burden on individuals with diabetes and the consumption of public medical resources. Despite the overall improvements in the prevention, diagnosis, and treatment of diabetic microvascular complications in recent years, safe and effective alternative or adjunctive therapies are urgently needed. The mechanisms underlying diabetic vascular complications are complex, with hyperglycemia-induced oxidative stress and inflammation being the leading causes. Therefore, glycemic control, antioxidation, and anti-inflammation are considered the main targets for the treatment of diabetes and its vascular comorbidities. Vaccinium L. (Ericaceae) is a genus of plants enriched with polyphenolic compounds in their leaves and fruits. Vaccinium and its extracts have demonstrated good bioactivity in reducing blood glucose, oxidative stress, and inflammation, making them excellent candidates for the management of diabetes and diabetic vascular complications. Here, we review recent preclinical and clinical studies on the potential effect of Vaccinium on ameliorating diabetes and diabetic complications, particularly diabetic kidney disease and diabetic retinopathy.
Collapse
Affiliation(s)
- Hui Huang
- National Clinical Research Center for Kidney Diseases, State Key Laboratory of Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, Beijing 100853, China
- School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Yayong Luo
- National Clinical Research Center for Kidney Diseases, State Key Laboratory of Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, Beijing 100853, China
- School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Qian Wang
- National Clinical Research Center for Kidney Diseases, State Key Laboratory of Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, Beijing 100853, China
| | - Yihan Zhang
- BYHEALTH Institute of Nutrition & Health, No. 3 Kehui 3rd Street, No. 99 Kexue Avenue Central, Huangpu District, Guangzhou 510663, China
| | - Zhongxia Li
- BYHEALTH Institute of Nutrition & Health, No. 3 Kehui 3rd Street, No. 99 Kexue Avenue Central, Huangpu District, Guangzhou 510663, China
| | - Ruikun He
- BYHEALTH Institute of Nutrition & Health, No. 3 Kehui 3rd Street, No. 99 Kexue Avenue Central, Huangpu District, Guangzhou 510663, China
| | - Xiangmei Chen
- National Clinical Research Center for Kidney Diseases, State Key Laboratory of Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, Beijing 100853, China
- School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Zheyi Dong
- National Clinical Research Center for Kidney Diseases, State Key Laboratory of Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, Beijing 100853, China
| |
Collapse
|
9
|
Wronka M, Krzemińska J, Młynarska E, Rysz J, Franczyk B. The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes. Int J Mol Sci 2022; 23:ijms232415743. [PMID: 36555387 PMCID: PMC9778895 DOI: 10.3390/ijms232415743] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Revised: 12/04/2022] [Accepted: 12/09/2022] [Indexed: 12/14/2022] Open
Abstract
Diabetes is considered a new pandemic of the modern world, and the number of sufferers is steadily increasing. Sustained hyperglycemia promotes the production of free radicals and leads to persistent, low-grade inflammation. Oxidative stress causes mitochondrial destruction, which along with activation of the hexosamine pathway, nuclear factor-κB (Nf-κb), p38 mitogen-activated protein kinase (p38 MAPK), c-jun NH2 terminal kinase/stress-activated protein kinase (JNK/SAPK) or toll-like receptors (TLRs), leads to pancreatic β-cell dysfunction. However, there is also the protective mechanism that counteracts oxidative stress and inflammation in diabetes, mitophagy, which is a mitochondrial autophagy. An important part of the strategy to control diabetes is to lead a healthy lifestyle based on, among other things, regular physical activity, giving up smoking, eating a balanced diet containing ingredients with antioxidant potential, including vegetables and fruits, and using hypoglycemic pharmacotherapy. Tobacco smoke is a recognized modifiable risk factor for many diseases including diabetes, and it has been shown that the risk of the disease increases in proportion to the intensity of smoking. Physical activity as another component of therapy can effectively reduce glucose fluctuations, and high intensity interval exercise appears to have the most beneficial effect. A proper diet not only increases cellular sensitivity to insulin, but is also able to reduce inflammation and oxidative stress. Pharmacotherapy for diabetes can also affect oxidative stress and inflammation. Some oral drugs, such as metformin, pioglitazone, vildagliptin, liraglutide, and exenatide, cause a reduction in markers of oxidative stress and/or inflammation, while the new drug Imeglimin reverses pancreatic β-cell dysfunction. In studies of sitagliptin, vildagliptin and exenatide, beneficial effects on oxidative stress and inflammation were achieved by, among other things, reducing glycemic excursions. For insulin therapy, no corresponding correlation was observed. Insulin did not reduce oxidative stress parameters. There was no correlation between glucose variability and oxidative stress in patients on insulin therapy. The data used in this study were obtained by searching PubMed online databases, taking into account recent studies.
Collapse
Affiliation(s)
- Magdalena Wronka
- Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland
| | - Julia Krzemińska
- Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland
| | - Ewelina Młynarska
- Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland
- Correspondence: ; Tel.: +48-(042)-6393750
| | - Jacek Rysz
- Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland
| | - Beata Franczyk
- Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland
| |
Collapse
|
10
|
Looi D, Moorthy M, Chaiyakunapruk N, Devi Palanisamy U. Impact of ellagitannin-rich fruit consumption on blood pressure: A systematic review and meta-analysis of randomized controlled trials. J Funct Foods 2022. [DOI: 10.1016/j.jff.2022.105320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Wang D, Wang T, Zhang Z, Li Z, Guo Y, Zhao G, Wu L. Recent advances in the effects of dietary polyphenols on inflammation in vivo: potential molecular mechanisms, receptor targets, safety issues, and uses of nanodelivery system and polyphenol polymers. Curr Opin Food Sci 2022. [DOI: 10.1016/j.cofs.2022.100921] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
12
|
Vendrame S, Adekeye TE, Klimis-Zacas D. The Role of Berry Consumption on Blood Pressure Regulation and Hypertension: An Overview of the Clinical Evidence. Nutrients 2022; 14:nu14132701. [PMID: 35807881 PMCID: PMC9268395 DOI: 10.3390/nu14132701] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 06/23/2022] [Accepted: 06/24/2022] [Indexed: 02/06/2023] Open
Abstract
The existence of a relationship between the consumption of dietary berries and blood pressure reduction in humans has been repeatedly hypothesized and documented by an increasing body of epidemiological and clinical evidence that has accumulated in recent years. However, results are mixed and complicated by a number of potentially confounding factors. The objective of this article is to review and summarize the available clinical evidence examining the effects of berry consumption on blood pressure regulation as well as the prevention or treatment of hypertension in humans, providing an overview of the potential contribution of distinctive berry polyphenols (anthocyanins, condensed tannins and ellagic acid), and results of dietary interventions with blueberries, bilberries, cranberries, raspberries, strawberries, chokeberries, cherries, blackcurrants and açai berries. We conclude that, while there is insufficient evidence supporting the existence of a direct blood pressure lowering effect, there is stronger evidence for specific types of berries acting indirectly to normalize blood pressure in subjects that are already hypertensive.
Collapse
|
13
|
Delpino FM, Figueiredo LM, Gonçalves da Silva T, Flores TR. Effects of blueberry and cranberry on type 2 diabetes parameters in individuals with or without diabetes: A systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2022; 32:1093-1109. [PMID: 35282984 DOI: 10.1016/j.numecd.2022.02.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 02/01/2022] [Accepted: 02/03/2022] [Indexed: 11/16/2022]
Abstract
AIMS Blueberry and cranberry are rich in polyphenols that are associated with diabetes reduction. This study aimed: 1) to systematically review the literature on the effects of blueberry and cranberry consumption and type 2 diabetes parameters in individuals with or without type 2 diabetes and 2) to quantify these effects by carrying out a meta-analysis. DATA SYNTHESIS A systematic review and meta-analysis were performed using articles present in seven databases (PubMed, LILACS, Scielo, Scopus, Web of Science, Cochrane, and Embase), including publications until May 2021. We included randomized clinical trials that compared blueberry or cranberry effects on type 2 diabetes parameters, such as fasting blood glucose, insulin resistance, and glycated hemoglobin. Quality of the studies was performed using the Cochrane scale, while the Egger test assessed the publication bias and meta-regression the estimated effect sizes with potential moderator variables. From the 2034 studies identified, 39 were read in full and 22 were included in meta-analysis. In individuals with diabetes, the consumption of blueberry or cranberry significantly reduced fasting blood glucose [MD: -17.72 mg/dl; 95% CI: -29.62, -5.82; p = 0.03; I2 = 57%] and glycated hemoglobin [MD: -0.32%; 95% CI: -0.57, -0.07; p = 0.15; I2 = 39%], whereas for insulin resistance the effects were null. Results were not significant for the general population, except in the sensitivity analysis for fasting blood glucose. CONCLUSIONS The consumption of blueberry and cranberry significantly reduced fasting blood glucose and glycated hemoglobin levels in individuals with diabetes, with high credibility of the evidence.
Collapse
Affiliation(s)
| | | | - Taiciane Gonçalves da Silva
- Postgraduate Program in Biotechnology, Faculty of Biotechnology, Federal University of Pelotas, Pelotas, Brazil
| | - Thaynã Ramos Flores
- Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, Brazil
| |
Collapse
|
14
|
Heiss C, Istas G, Feliciano RP, Weber T, Wang B, Favari C, Mena P, Del Rio D, Rodriguez-Mateos A. Daily consumption of cranberry improves endothelial function in healthy adults: a double blind randomized controlled trial. Food Funct 2022; 13:3812-3824. [PMID: 35322843 DOI: 10.1039/d2fo00080f] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Background: Previous studies indicate cardiovascular health benefits of cranberry juice consumption. However, whether daily consumption of whole cranberries will have sustained vascular benefits in healthy individuals is currently unknown. Objective: To investigate the vascular effects of acute and daily consumption of freeze dried whole cranberry in healthy men and how effects relate to circulating cranberry (poly)phenol metabolites. Methods: A double-blind, parallel-group, randomized controlled trial was conducted in 45 healthy male adults randomly allocated to 1 month daily consumption of either cranberry (9 g powder solubilized in water equivalent to 100 g of fresh cranberries, 525 mg total (poly)phenols) or control (9 g powder, no (poly)phenols). Flow-mediated dilation (FMD, primary outcome), pulse wave velocity (PWV), aortic augmentation index (AIx), blood pressure, heart rate, blood lipids, and blood glucose were assessed at baseline and at 2 h on day 1 and after 1 month. Plasma and 24 h-urine were analyzed before and after treatment using targeted quantitative LC-MS methods including 137 (poly)phenol metabolites. Results: Cranberry consumption significantly increased FMD at 2 h and 1-month (1.1% (95% CI: 1.1%, 1.8%); ptreatment ≤ 0.001; ptreatment × time = 0.606) but not PWV, AIx, blood pressure, heart rate, blood lipids, and glucose. Of the 56 and 74 (poly)phenol metabolites quantified in plasma and urine, 13 plasma and 13 urinary metabolites significantly increased 2 h post-consumption and on day 1, respectively, while 4 plasma and 13 urinary metabolites were significantly higher after 1-month of cranberry consumption, in comparison with control. A multi-variable stepwise linear regression analysis showed that plasma cinnamic acid-4'-glucuronide, 4-hydroxybenzoic acid-3-sulfate, 2,5-dihydroxybenzoic acid, 3'-hydroxycinnamic acid, and 5-O-caffeoylquinic acid were significant independent predictors of 2 h FMD effects (R2 = 0.71), while 3'-hydroxycinnamic acid, 4-methoxycinnamic acid-3'-glucuronide, 3-(4'-methoxyphenyl)propanoic acid 3'-sulfate, and 3-(4'-methoxyphenyl)propanoic acid 3'-glucuronide predicted the 1-month FMD effects (R2 = 0.52). Conclusions: Acute and daily consumption of whole cranberry powder for 1 month improves vascular function in healthy men and this is linked with specific metabolite profiles in plasma. The National Institutes of Health (NIH)-randomized trial records held on the NIH ClinicalTrials.gov website (NCT02764749). https://clinicaltrials.gov/ct2/show/NCT02764749.
Collapse
Affiliation(s)
- Christian Heiss
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Düsseldorf, Düsseldorf, Germany.,Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.,Surrey and Sussex Healthcare NHS Trust, East Surrey Hospital, Redhill, UK
| | - Geoffrey Istas
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Düsseldorf, Düsseldorf, Germany.,Department of Nutritional Sciences, School of Life Course and Population Health Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK.
| | - Rodrigo P Feliciano
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Düsseldorf, Düsseldorf, Germany
| | - Timon Weber
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Düsseldorf, Düsseldorf, Germany
| | - Brian Wang
- Department of Nutritional Sciences, School of Life Course and Population Health Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK.
| | - Claudia Favari
- Human Nutrition Unit, Department of Food & Drug, University of Parma, Parma, Italy
| | - Pedro Mena
- Human Nutrition Unit, Department of Food & Drug, University of Parma, Parma, Italy.,Microbiome Research Hub, University of Parma, Parma, Italy
| | - Daniele Del Rio
- Human Nutrition Unit, Department of Food & Drug, University of Parma, Parma, Italy.,Microbiome Research Hub, University of Parma, Parma, Italy.,School of Advanced Studies on Food and Nutrition, University of Parma, Parma, Italy
| | - Ana Rodriguez-Mateos
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Düsseldorf, Düsseldorf, Germany.,Department of Nutritional Sciences, School of Life Course and Population Health Sciences, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK.
| |
Collapse
|
15
|
Fernandes I, Oliveira J, Pinho A, Carvalho E. The Role of Nutraceutical Containing Polyphenols in Diabetes Prevention. Metabolites 2022; 12:metabo12020184. [PMID: 35208257 PMCID: PMC8878446 DOI: 10.3390/metabo12020184] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/11/2022] [Accepted: 02/14/2022] [Indexed: 01/27/2023] Open
Abstract
Research in pharmacological therapy has led to the availability of many antidiabetic agents. New recommendations for precision medicine and particularly precision nutrition may greatly contribute to the control and especially to the prevention of diabetes. This scenario greatly encourages the search for novel non-pharmaceutical molecules. In line with this, the daily and long-term consumption of diets rich in phenolic compounds, together with a healthy lifestyle, may have a protective role against the development of type 2 diabetes. In the framework of the described studies, there is clear evidence that the bio accessibility, bioavailability, and the gut microbiota are indeed affected by: the way phenolic compounds are consumed (acutely or chronically; as pure compounds, extracts, or in-side a whole meal) and the amount and the type of phenolic compounds (ex-tractable or non-extractable/macromolecular antioxidants, including non-bioavailable polyphenols and plant matrix complexed structures). In this review, we report possible effects of important, commonly consumed, phenolic-based nutraceuticals in pre-clinical and clinical diabetes studies. We highlight their mechanisms of action and their potential effects in health promotion. Translation of this nutraceutical-based approach still requires more and larger clinical trials for better elucidation of the mechanism of action toward clinical applications.
Collapse
Affiliation(s)
- Iva Fernandes
- Laboratório Associado para a Química Verde—REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, 687, 4169-007 Porto, Portugal;
| | - Joana Oliveira
- Laboratório Associado para a Química Verde—REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, 687, 4169-007 Porto, Portugal;
- Correspondence: (J.O.); (E.C.)
| | - Aryane Pinho
- Center for Neuroscience and Cell Biology, Faculdade de Medicina, University of Coimbra, Rua Larga, Polo I, 1º Andar, 3004-504 Coimbra, Portugal; or
- Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal
| | - Eugenia Carvalho
- Center for Neuroscience and Cell Biology, Faculdade de Medicina, University of Coimbra, Rua Larga, Polo I, 1º Andar, 3004-504 Coimbra, Portugal; or
- Instituto de Investigação Interdisciplinar, University of Coimbra, Casa Costa Alemão, Rua Dom Francisco de Lemos, 3030-789 Coimbra, Portugal
- APDP—Portuguese Diabetes Association, 1250-189 Lisbon, Portugal
- Correspondence: (J.O.); (E.C.)
| |
Collapse
|
16
|
Tresserra-Rimbau A, Castro-Barquero S, Becerra-Tomás N, Babio N, Martínez-González MÁ, Corella D, Fitó M, Romaguera D, Vioque J, Alonso-Gomez AM, Wärnberg J, Martínez JA, Serra-Majem L, Estruch R, Tinahones FJ, Lapetra J, Pintó X, Tur JA, López-Miranda J, Cano-Ibáñez N, Delgado-Rodríguez M, Matía-Martín P, Daimiel L, Martín Sánchez V, Vidal J, Vázquez C, Ros E, Basterra FJ, Fernández de la Puente M, Asensio EM, Castañer O, Bullón-Vela V, Tojal-Sierra L, Gómez-Gracia E, Cases-Pérez E, Konieczna J, García-Ríos A, Casañas-Quintana T, Bernal-Lopez MR, Santos-Lozano JM, Esteve-Luque V, Bouzas C, Vázquez-Ruiz Z, Palau-Galindo A, Barragan R, López Grau M, Razquín C, Goicolea-Güemez L, Toledo E, Vergaz MV, Lamuela-Raventós RM, Salas-Salvadó J. Adopting a High-Polyphenolic Diet Is Associated with an Improved Glucose Profile: Prospective Analysis within the PREDIMED-Plus Trial. Antioxidants (Basel) 2022; 11:antiox11020316. [PMID: 35204199 PMCID: PMC8868059 DOI: 10.3390/antiox11020316] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 01/30/2022] [Accepted: 02/01/2022] [Indexed: 02/05/2023] Open
Abstract
Previous studies suggested that dietary polyphenols could reduce the incidence and complications of type-2 diabetes (T2D); although the evidence is still limited and inconsistent. This work analyzes whether changing to a diet with a higher polyphenolic content is associated with an improved glucose profile. At baseline, and at 1 year of follow-up visits, 5921 participants (mean age 65.0 ± 4.9, 48.2% women) who had overweight/obesity and metabolic syndrome filled out a validated 143-item semi-quantitative food frequency questionnaire (FFQ), from which polyphenol intakes were calculated. Energy-adjusted total polyphenols and subclasses were categorized in tertiles of changes. Linear mixed-effect models with random intercepts (the recruitment centers) were used to assess associations between changes in polyphenol subclasses intake and 1-year plasma glucose or glycosylated hemoglobin (HbA1c) levels. Increments in total polyphenol intake and some classes were inversely associated with better glucose levels and HbA1c after one year of follow-up. These associations were modified when the analyses were run considering diabetes status separately. To our knowledge, this is the first study to assess the relationship between changes in the intake of all polyphenolic groups and T2D-related parameters in a senior population with T2D or at high-risk of developing T2D.
Collapse
Affiliation(s)
- Anna Tresserra-Rimbau
- Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, 08921 Barcelona, Spain;
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Correspondence:
| | - Sara Castro-Barquero
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Nerea Becerra-Tomás
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
| | - Nancy Babio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
| | - Miguel Ángel Martínez-González
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Dolores Corella
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Montserrat Fitó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Dora Romaguera
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
| | - Jesús Vioque
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Alicante Institute for Health and Biomedical Research, University Miguel Hernandez (ISABIAL-UMH), 03010 Alicante, Spain
| | - Angel M. Alonso-Gomez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Julia Wärnberg
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nursing, Institute of Biomedical Research in Málaga (IBIMA), University of Málaga, 29010 Malaga, Spain
| | - José Alfredo Martínez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
- Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
| | - Luís Serra-Majem
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, 35016 Las Palmas de Gran Canaria, Spain
| | - Ramon Estruch
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Francisco J. Tinahones
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Regional University Hospital of Malaga, Instituto de Investigación Biomédica de Malaga (IBIMA), University of Malaga, 29010 Malaga, Spain
| | - José Lapetra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41010 Sevilla, Spain
| | - Xavier Pintó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, 08908 Hospitalet de Llobregat, Spain;
| | - Josep A. Tur
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain
| | - José López-Miranda
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | - Naomi Cano-Ibáñez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Department of Preventive Medicine and Public Health, University of Granada, 18016 Granada, Spain
- Instituto de Investigación Biosanitaria, Complejo Hospitales Universitarios de Granada, Universidad de Granada, 18016 Granada, Spain
| | - Miguel Delgado-Rodríguez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Division of Preventive Medicine, Faculty of Medicine, University of Jaén, 23071 Jaen, Spain
| | - Pilar Matía-Martín
- Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain;
| | - Lidia Daimiel
- Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, 28029 Madrid, Spain;
| | - Vicente Martín Sánchez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Institute of Biomedicine (IBIOMED), University of León, 24071 Leon, Spain
| | - Josep Vidal
- CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
- Department of Endocrinology, Institut d’Investigacions Biomédiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Clotilde Vázquez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Endocrinology and Nutrition, Hospital Fundación Jimenez Díaz, Instituto de Investigaciones Biomédicas IISFJD, University Autonoma, 28040 Madrid, Spain
| | - Emili Ros
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain
| | - Francisco Javier Basterra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
| | - María Fernández de la Puente
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
| | - Eva M. Asensio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Olga Castañer
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Vanessa Bullón-Vela
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
| | - Lucas Tojal-Sierra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Enrique Gómez-Gracia
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, Instituto de Investigación Biomédica de Málaga-IBIMA, School of Medicine, University of Málaga, 29071 Malaga, Spain
| | | | - Jadwiga Konieczna
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
| | - Antonio García-Ríos
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | - Tamara Casañas-Quintana
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, 35016 Las Palmas de Gran Canaria, Spain
| | - María Rosa Bernal-Lopez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Regional University Hospital of Malaga, Instituto de Investigación Biomédica de Malaga (IBIMA), University of Malaga, 29010 Malaga, Spain
| | - José Manuel Santos-Lozano
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41010 Sevilla, Spain
| | - Virginia Esteve-Luque
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, 08908 Hospitalet de Llobregat, Spain;
| | - Cristina Bouzas
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain
| | - Zenaida Vázquez-Ruiz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
| | - Antoni Palau-Galindo
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- ABS Reus V. Centre d’Assistència Primària Marià Fortuny, SAGESSA, 43205 Reus, Spain
| | - Rocio Barragan
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Mercè López Grau
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Cristina Razquín
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
- Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
| | - Leire Goicolea-Güemez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Estefanía Toledo
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Manel Vila Vergaz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Rosa M. Lamuela-Raventós
- Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, 08921 Barcelona, Spain;
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
| | - Jordi Salas-Salvadó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
| |
Collapse
|
17
|
Highly Active Cranberry's Polyphenolic Fraction: New Advances in Processing and Clinical Applications. Nutrients 2021; 13:nu13082546. [PMID: 34444706 PMCID: PMC8399388 DOI: 10.3390/nu13082546] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2021] [Revised: 07/21/2021] [Accepted: 07/22/2021] [Indexed: 02/07/2023] Open
Abstract
Cranberry is a fruit originally from New England and currently growing throughout the east and northeast parts of the USA and Canada. The supplementation of cranberry extracts as nutraceuticals showed to contribute to the prevention of urinary tract infections, and most likely it may help to prevent cardiovascular and gastroenteric diseases, as highlighted by several clinical trials. However, aiming to validate the efficacy and safety of clinical applications as long-term randomized clinical trials (RCTs), further investigations of the mechanisms of action are required. In addition, a real challenge for next years is the standardization of cranberry’s polyphenolic fractions. In this context, the optimization of the extraction process and downstream processing represent a key point for a reliable active principle for the formulation of a food supplement. For this reason, new non-conventional extraction methods have been developed to improve the quality of the extracts and reduce the overall costs. The aim of this survey is to describe both technologies and processes for highly active cranberry extracts as well as the effects observed in clinical studies and the respective tolerability notes.
Collapse
|
18
|
Al Othaim A, Marasini D, Carbonero F. Impact of cranberry juice consumption on gut and vaginal microbiota in postmenopausal women. FOOD FRONTIERS 2021. [DOI: 10.1002/fft2.76] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- Ayoub Al Othaim
- Cell and Molecular Biology Program University of Arkansas Fayetteville Arkansas USA
- Department of Medical Laboratories College of Applied Medical Sciences Majmaah University Al‐Majmaah Saudi Arabia
| | - Daya Marasini
- Department of Food Science University of Arkansas Fayetteville Arkansas USA
| | - Franck Carbonero
- Cell and Molecular Biology Program University of Arkansas Fayetteville Arkansas USA
- Department of Food Science University of Arkansas Fayetteville Arkansas USA
- Department of Food Science Washington State University Spokane Washington USA
- Department of Nutrition and Exercise Physiology Elson Floyd School of Medicine Washington State University Spokane Spokane Washington USA
| |
Collapse
|
19
|
Da Porto A, Cavarape A, Colussi G, Casarsa V, Catena C, Sechi LA. Polyphenols Rich Diets and Risk of Type 2 Diabetes. Nutrients 2021; 13:nu13051445. [PMID: 33923263 PMCID: PMC8146556 DOI: 10.3390/nu13051445] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 04/16/2021] [Accepted: 04/21/2021] [Indexed: 01/13/2023] Open
Abstract
Type 2 diabetes is an increasing health concern worldwide. Both genetic and environmental risk factors as improper dietary habits or physical inactivity are known to be crucial in the pathogenesis of type 2 diabetes. Polyphenols are a group of plant-derived compounds with anti-inflammatory and antioxidant properties that are associated with a low prevalence of metabolic conditions characterized by insulin resistance, including obesity, diabetes, and hypertension. Moreover, there is now full awareness that foods that are rich in phytochemicals and polyphenols could play an important role in preserving human cardiovascular health and substantial clinical evidence indicates that regular dietary consumption of such foods affects favorably carbohydrate metabolism. This review briefly summarizes the evidence relating dietary patterns rich in polyphenols with glucose metabolism and highlights the potential benefits of these compounds in the prevention of type 2 diabetes.
Collapse
|
20
|
Basu A, Izuora K, Betts NM, Kinney JW, Salazar AM, Ebersole JL, Scofield RH. Dietary Strawberries Improve Cardiometabolic Risks in Adults with Obesity and Elevated Serum LDL Cholesterol in a Randomized Controlled Crossover Trial. Nutrients 2021; 13:nu13051421. [PMID: 33922576 PMCID: PMC8145532 DOI: 10.3390/nu13051421] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 04/21/2021] [Accepted: 04/22/2021] [Indexed: 02/08/2023] Open
Abstract
Background and aims: Dietary berries, such as strawberries, are rich in bioactive compounds and have been shown to lower cardiometabolic risk. We examined the effects of two dietary achievable doses of strawberries on glycemic control and lipid profiles in obese adults with elevated serum LDL cholesterol (LDL-C). Methods: In this 14-week randomized controlled crossover study, participants were assigned to one of the three arms for four weeks separated by a one-week washout period: control powder, one serving (low dose: 13 g strawberry powder/day), or two-and-a -half servings (high dose: 32 g strawberry powder/day). Participants were instructed to follow their usual diet and lifestyle while refraining from consuming other berries and related products throughout the study interval. Blood samples, anthropometric measures, blood pressure, and dietary and physical activity data were collected at baseline and at the end of each four-week phase of intervention. Results: In total, 33 participants completed all three phases of the trial [(mean ± SD): Age: 53 ± 13 y; BMI: 33 ± 3.0 kg/m2). Findings revealed significant reductions in fasting insulin (p = 0.0002) and homeostatic model of assessment of insulin resistance (p = 0.0003) following the high dose strawberry phase when compared to the low dose strawberry and control phases. Glucose and conventional lipid profiles did not differ among the phases. Nuclear magnetic resonance-determined particle concentrations of total VLDL and chylomicrons, small VLDL, and total and small LDL were significantly decreased after the high dose strawberry phase, compared to control and low dose phases (all p < 0.0001). Among the biomarkers of inflammation and adipokines measured, only serum PAI-1 showed a decrease after the high dose strawberry phase (p = 0.002). Conclusions: These data suggest that consuming strawberries at two-and-a-half servings for four weeks significantly improves insulin resistance, lipid particle profiles, and serum PAI-1 in obese adults with elevated serum LDL-C.
Collapse
Affiliation(s)
- Arpita Basu
- Department of Kinesiology and Nutrition Sciences, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV 89154, USA
- Correspondence: ; Tel.: +1-702-895-4576; Fax: +1-702-895-1500
| | - Kenneth Izuora
- Section of Endocrinology, School of Medicine, University of Nevada, Las Vegas, NV 89154, USA;
| | - Nancy M. Betts
- Department of Nutritional Sciences, Oklahoma State University, Stillwater, OK 74078, USA;
| | - Jefferson W. Kinney
- Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV 89154, USA; (J.W.K.); (A.M.S.)
| | - Arnold M. Salazar
- Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV 89154, USA; (J.W.K.); (A.M.S.)
| | | | - R. Hal Scofield
- Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA;
- Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
| |
Collapse
|
21
|
Leclerc M, Dudonné S, Calon F. Can Natural Products Exert Neuroprotection without Crossing the Blood-Brain Barrier? Int J Mol Sci 2021; 22:ijms22073356. [PMID: 33805947 PMCID: PMC8037419 DOI: 10.3390/ijms22073356] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 03/19/2021] [Accepted: 03/20/2021] [Indexed: 12/17/2022] Open
Abstract
The scope of evidence on the neuroprotective impact of natural products has been greatly extended in recent years. However, a key question that remains to be answered is whether natural products act directly on targets located in the central nervous system (CNS), or whether they act indirectly through other mechanisms in the periphery. While molecules utilized for brain diseases are typically bestowed with a capacity to cross the blood–brain barrier, it has been recently uncovered that peripheral metabolism impacts brain functions, including cognition. The gut–microbiota–brain axis is receiving increasing attention as another indirect pathway for orally administered compounds to act on the CNS. In this review, we will briefly explore these possibilities focusing on two classes of natural products: omega-3 polyunsaturated fatty acids (n-3 PUFAs) from marine sources and polyphenols from plants. The former will be used as an example of a natural product with relatively high brain bioavailability but with tightly regulated transport and metabolism, and the latter as an example of natural compounds with low brain bioavailability, yet with a growing amount of preclinical and clinical evidence of efficacy. In conclusion, it is proposed that bioavailability data should be sought early in the development of natural products to help identifying relevant mechanisms and potential impact on prevalent CNS disorders, such as Alzheimer’s disease.
Collapse
Affiliation(s)
- Manon Leclerc
- Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada;
- Axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Québec, QC G1V 4G2, Canada
- Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Québec, QC G1V 0A6, Canada;
- OptiNutriBrain-Laboratoire International Associé (NutriNeuro France-INAF Canada), Québec, QC G1V 0A6, Canada
| | - Stéphanie Dudonné
- Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Québec, QC G1V 0A6, Canada;
- OptiNutriBrain-Laboratoire International Associé (NutriNeuro France-INAF Canada), Québec, QC G1V 0A6, Canada
| | - Frédéric Calon
- Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada;
- Axe Neurosciences, Centre de Recherche du CHU de Québec–Université Laval, Québec, QC G1V 4G2, Canada
- Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Québec, QC G1V 0A6, Canada;
- OptiNutriBrain-Laboratoire International Associé (NutriNeuro France-INAF Canada), Québec, QC G1V 0A6, Canada
- Correspondence: ; Tel.: +1-(418)-525-4444 (ext. 48697); Fax: +1-(418)-654-2761
| |
Collapse
|
22
|
Cammisotto V, Nocella C, Bartimoccia S, Sanguigni V, Francomano D, Sciarretta S, Pastori D, Peruzzi M, Cavarretta E, D’Amico A, Castellani V, Frati G, Carnevale R, Group SM. The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors. Antioxidants (Basel) 2021; 10:146. [PMID: 33498338 PMCID: PMC7909411 DOI: 10.3390/antiox10020146] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 01/08/2021] [Accepted: 01/18/2021] [Indexed: 12/15/2022] Open
Abstract
Oxidative stress may be defined as an imbalance between reactive oxygen species (ROS) and the antioxidant system to counteract or detoxify these potentially damaging molecules. This phenomenon is a common feature of many human disorders, such as cardiovascular disease. Many of the risk factors, including smoking, hypertension, hypercholesterolemia, diabetes, and obesity, are associated with an increased risk of developing cardiovascular disease, involving an elevated oxidative stress burden (either due to enhanced ROS production or decreased antioxidant protection). There are many therapeutic options to treat oxidative stress-associated cardiovascular diseases. Numerous studies have focused on the utility of antioxidant supplementation. However, whether antioxidant supplementation has any preventive and/or therapeutic value in cardiovascular pathology is still a matter of debate. In this review, we provide a detailed description of oxidative stress biomarkers in several cardiovascular risk factors. We also discuss the clinical implications of the supplementation with several classes of antioxidants, and their potential role for protecting against cardiovascular risk factors.
Collapse
Affiliation(s)
- Vittoria Cammisotto
- Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, 00185 Rome, Italy
| | - Cristina Nocella
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy; (S.B.); (D.P.); (V.C.)
| | - Simona Bartimoccia
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy; (S.B.); (D.P.); (V.C.)
| | - Valerio Sanguigni
- Unit of Internal Medicine and Endocrinology, Madonna delle Grazie Hospital, Velletri, 00049 Rome, Italy; (V.S.); (D.F.)
- Department of Internal Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Davide Francomano
- Unit of Internal Medicine and Endocrinology, Madonna delle Grazie Hospital, Velletri, 00049 Rome, Italy; (V.S.); (D.F.)
| | - Sebastiano Sciarretta
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy; (S.S.); (M.P.); (E.C.); (G.F.)
- Department of AngioCardioNeurology, IRCCS Neuromed, 86077 Pozzilli, Italy
| | - Daniele Pastori
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy; (S.B.); (D.P.); (V.C.)
| | - Mariangela Peruzzi
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy; (S.S.); (M.P.); (E.C.); (G.F.)
- Mediterranea, Cardiocentro, 80122 Napoli, Italy
| | - Elena Cavarretta
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy; (S.S.); (M.P.); (E.C.); (G.F.)
- Mediterranea, Cardiocentro, 80122 Napoli, Italy
| | - Alessandra D’Amico
- Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, 00135 Rome, Italy;
| | - Valentina Castellani
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy; (S.B.); (D.P.); (V.C.)
| | - Giacomo Frati
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy; (S.S.); (M.P.); (E.C.); (G.F.)
- Department of AngioCardioNeurology, IRCCS Neuromed, 86077 Pozzilli, Italy
| | - Roberto Carnevale
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy; (S.S.); (M.P.); (E.C.); (G.F.)
- Mediterranea, Cardiocentro, 80122 Napoli, Italy
| | - SMiLe Group
- Faculty of Medicine and Surgery, Sapienza University of Rome, 04100 Latina, Italy;
| |
Collapse
|
23
|
Arruda HS, Neri-Numa IA, Kido LA, Maróstica Júnior MR, Pastore GM. Recent advances and possibilities for the use of plant phenolic compounds to manage ageing-related diseases. J Funct Foods 2020. [DOI: 10.1016/j.jff.2020.104203] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
24
|
Fallah AA, Sarmast E, Jafari T. Effect of dietary anthocyanins on biomarkers of glycemic control and glucose metabolism: A systematic review and meta-analysis of randomized clinical trials. Food Res Int 2020; 137:109379. [PMID: 33233081 DOI: 10.1016/j.foodres.2020.109379] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 05/28/2020] [Accepted: 06/02/2020] [Indexed: 01/20/2023]
Abstract
Anthocyanins, as natural food colorants, are bioactive substances with several health advantages. In this research, the effects of dietary anthocyanins on biomarkers of glycemic control and glucose metabolism was evaluated through a meta-analysis. The results revealed a significant reduction in levels of fasting blood sugar (FBS; -2.70 mg/dl, 95% CI: -4.70 to -1.31; P < 0.001), 2-h postprandial glucose (2-h PPG; -11.1 mg/dl, 95% CI: -18.7 to -3.48; P = 0.004), glycated hemoglobin (HbA1c; -11.1 mg/dl, 95% CI: -18.7 to -3.48; P = 0.004), homeostasis model assessment of insulin resistance (HOMA-IR; -0.54, 95% CI: -0.94 to -0.14; P = 0.008), resistin (-1.23 µg/l, 95% CI: -2.40 to -0.05; P = 0.041), and plasminogen activator inhibitor-1 (PAI-1; -5.09 µg/l, 95% CI: -9.45 to -0.73; P = 0.022) following administration of anthocyanins, whilst changes in the levels of fasting insulin (0.33 mU/l, 95% CI: -0.18 to 0.85; P = 0.207) and C-peptide (-0.02 µg/l, 95 %CI: -0.20 to 0.16; P = 0.816) was not statistically significant. Consumption of anthocyanins for >8 weeks and at doses >300 mg/day significantly reduced levels of FBS, 2-h PPG, HbA1c, and HOMA-IR. Moreover, anthocyanins administration reduced the levels of FBS, 2-h PPG, HbA1c, and HOMA-IR in type 2 diabetic subjects and HOMA-IR in overweight/obese individuals. Overall, dietary anthocyanins can be used as an adjuvant therapy to improve biomarkers of glycemic control and glucose metabolism specially in diabetic subjects.
Collapse
Affiliation(s)
- Aziz A Fallah
- Department of Food Hygiene and Quality Control, Faculty of Veterinary Medicine, Shahrekord University, Shahrekord 34141, Iran
| | - Elham Sarmast
- Department of Food Hygiene and Quality Control, Faculty of Veterinary Medicine, Shahrekord University, Shahrekord 34141, Iran
| | - Tina Jafari
- Department of Biochemistry and Nutrition, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
| |
Collapse
|